

12

# EUROPEAN PATENT APPLICATION

21 Application number: 82106599.2

51 Int. Cl.<sup>3</sup>: C 12 N 15/00

C 07 H 21/04, C 12 N 1/20

22 Date of filing: 21.07.82

30 Priority: 17.08.81 US 293614

43 Date of publication of application:  
02.03.83 Bulletin 83/9

84 Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

71 Applicant: Rutgers Research and Educational  
Foundation

New Brunswick New Jersey(US)


72 Inventor: Simon, Lee D.  
311 South 41 Street  
Philadelphia, Pa. 19104(US)

72 Inventor: Fay, Rose B.  
98A Rutgers Road  
Piscataway New Jersey 08854(US)

74 Representative: Vossius Vossius-Tauchner Heunemann  
Rauh  
Siebertstrasse 4 P.O. Box 86 07 67  
D-8000 München 86(DE)

54 T4 DNA fragment as a stabilizer for proteins expressed by cloned DNA.

57 A DNA fragment isolated from the DNA of T-even bacteriophage which suppresses the degradation of abnormal proteins in bacterial cells is disclosed. The DNA fragment can be isolated by treating the DNA of T-even bacteriophage with a restriction enzyme to cleave the DNA into fragments, at least one of said fragments consisting essentially of a sequence of nucleotide bases which code for protein that functions to suppress degradation of abnormal proteins in bacterial cells, inserting the DNA fragments into cloning vehicles, such as plasmids, to produce hybrid cloning vehicles, transforming bacterial cells by introducing the hybrid cloning vehicles therein, and selecting the transformants which exhibit suppressed protein degradation mechanisms. The DNA fragment can then be isolated from the selected transformants. The stabilizing DNA fragment can be introduced into bacterial host cells to increase the yield of foreign proteins expressed by cloned DNA.



EP 0 072 925 A2

1

July 21, 1982

5 Our Ref.: R 977 EP (Ra )

Case: 18 845-EPO

Rutgers Research and Educational Foundation

New Brunswick, N.J., USA

10 "T4 DNA Fragment as a Stabilizer for Proteins Expressed  
by Cloned DNA".

Background of the invention

15

This invention relates to the field of recombinant DNA.  
In one of its aspects, this invention relates to a DNA  
fragment which inhibits degradation of abnormal proteins  
in bacterial cells. In another aspect, this invention  
20 relates to a method of isolating this stabilizing DNA  
fragment from T-even phage particles. In another aspect,  
this invention relates to a plasmid containing the  
stabilizing DNA fragment. In yet another aspect, this  
invention relates to a method of amplifying foreign  
25 proteins encoded by cloned DNA by including the stabi-  
lizing DNA fragment into the genetic machinery of bacterial  
host cells.

30

Most living cells possess efficient systems for recog-  
nizing and eliminating abnormal proteins. As used herein,  
the term "abnormal proteins" refers to proteins with  
abnormal conformations, protein fragments, polypeptide  
sequences containing amino acid analogues, missense  
mutant proteins, nonsense protein fragments, proteins en-  
35 coded by cloned DNA and other polypeptides not ordin-  
arily present in healthy, viable cells. In E. coli cells,  
for example, the half-lives of protein fragments and  
protein with abnormal conformations are much shorter

than the half-lives of normal proteins. About 3% of normal proteins turns over each hour in E. coli cells. Abnormal proteins, however, are so short-lived that they are found in much lower quantities than normal proteins or fail to accumulate to detectable levels.

Little is known about the mechanism by which living cells detect and degrade abnormal proteins. Some information is available about this system in E. coli cells. See, for example, Simon et al., Nature, 275, 424 (1978). It is known that the degradation of abnormal proteins in E. coli cells is ATP-dependent. If cellular ATP levels are substantially reduced, the turnover of abnormal proteins and protein fragments is also reduced. It is also believed that the ATP-dependent degradative mechanism is bound to the E. coli cell membrane. However, the identities and functions of the enzymes responsible for recognizing and degrading abnormal proteins remain obscure in E. coli and in other bacterial cells.

The degradation systems possessed by living cells present a major obstacle to the manufacture of useful proteins by means of recombinant DNA or molecular cloning procedures. By these procedures, the genes which code for eukaryotic proteins are introduced into host cells, such as bacterial cells, which then express the foreign genes as the eukaryotic proteins. The recombinant DNA procedures involve isolating the relevant genes, inserting them into suitable cloning vehicles, such as bacterial plasmids or viruses, and transforming host cells by introducing the hybrid cloning vehicles into the cells. The transformed cells which contain the relevant genes are then selected from all the other cells

and are grown in cultures. By such techniques, bacterial cells have been induced thus far to manufacture human growth hormone, human insulin, human interferon, etc. However, the bacterial cells apparently recognize these products as abnormal proteins, and under most circumstances, degrade them. Thus, the ability of living cells to detect and degrade abnormal proteins may severely limit the yields of useful proteins obtained from cloned cells.

To increase such yields, it would be highly desirable to provide a method for inhibiting or suppressing the degradation mechanism in cells carrying cloned genes. Such a method, when combined with already known recombinant DNA methods, would provide a highly efficient means for producing useful proteins.

It has previously been reported that the bacteriophage known as T4 influences the degradation function in E. coli cells. Simon et al., in Nature, supra, reported that T4 infection of E. coli cells inhibits degradation of abnormal polypeptide sequences but does not affect the turnover rate of normal bacterial proteins. In the studies reported therein, it was found that adsorption of T4 particles to the E. coli surface and injection of T4 DNA were not by themselves sufficient to alter protein turnover. It was found that inhibition of degradation requires the synthesis of early T4 proteins. It was also reported therein that other phages, such as T5 and T7, also inhibit degradation in E. coli cells but not so to great an extent as does T4 phage. However, infecting E. coli cells with T4, T5 or T7, phage particles is fatal to the host cells, and this method is unsuitable for amplifying proteins expressed by cloned DNA.

1 The bacteriophage T4 together with the bacteriophages T2  
and T6 form a family of bacteriophages known as T-even  
phages. The T-even phages are almost identical in  
structure, composition and properties. Thus, one of  
5 ordinary skill in the art would conclude that all members  
of the T-even bacteriophage family contain genes which  
suppress degradation.

In order to maximize the yields of eukaryotic proteins  
10 produced by recombinant DNA techniques, it would be  
highly desirable to excise from T-even phages, especially  
T4 phage particles the gene(s) responsible for inhibiting  
the degradation mechanism and to insert the same gene(s)  
into bacterial host cells. In this manner, the degradation  
15 mechanism of cells carrying cloned DNA can be turned  
off without killing the cells as by infection with T4  
phage particles.

It is an object of the invention to provide a DNA frag-  
20 ment from T-even phage particles which will inhibit the  
degradation of abnormal proteins in bacterial host cells.

It is another object of the invention to provide a cloning  
vehicle such as a bacterial plasmid, which contains the  
25 stabilizing T-even DNA fragment.

It is another object of the invention to provide bacterial  
cells containing the hybrid cloning vehicle with the  
stabilizing T-even DNA fragment.  
30

It is still another object of the invention to provide  
transformants which contain the genes for producing  
eukaryotic proteins as well as the stabilizing T4 DNA  
fragment.  
35

It is still another object of the invention to provide  
a method for suppressing the degradation of abnormal

1 proteins in a bacterial cell.

It is still another object of the invention to provide  
a DNA fragment coding for protein that suppresses de-  
5 gradation of abnormal proteins in bacterial cells.

These objects are accomplished by means of the present  
invention.

10 Summary of the invention

A primary subject matter of the invention is a DNA frag-  
ment isolated from the DNA of a T-even bacteriophage,  
said DNA fragment consisting essentially of a sequence  
15 of nucleotide bases which code for protein that suppresses  
degradation of abnormal polypeptides in bacterial cells.

The said DNA fragment may be a fragment wherein the  
nucleotide bases code for protein that suppresses de-  
20 gradation in gram-negative bacterial cells.

Preferably the said DNA fragment is a fragment wherein  
the nucleotide bases code for protein that suppresses  
degradation in E. coli cells.

25

The said DNA fragment may also be a fragment wherein the  
nucleotide bases code for protein that suppresses degra-  
dation in Pseudomonas, Aerobacter, Salmonella, Proteus  
or Serratia cells.

30

The said DNA fragment can further be a fragment wherein  
the nucleotide bases code for protein that suppresses  
degradation in gram-positive bacterial cells.

35 Preferably the latter DNA fragment is a fragment wherein  
the nucleotide bases code for protein that suppresses  
degradation in Bacillus subtilis cells.

1 Preferably, the said DNA fragment is isolated from T4  
bacteriophage. This DNA fragment preferably comes from  
the vicinity of gene 49 of the T4 genetic map.

5 The T-even DNA from which the DNA fragment of the invention stems is preferably cytosine-containing and nonglucosylated.

Another subject matter of the invention is a hybrid  
10 cloning vehicle comprising a cloning vehicle and the DNA fragment of the invention.

Said cloning vehicle of the invention is preferably a plasmid, the plasmid pBR 325 being especially preferred.

15

In another aspect of the invention the hybrid cloning vehicle further comprises a sequence of nucleotide bases coding for a eukaryotic, preferably human, protein.

20 The said human protein is preferably human interferon.

Another subject matter of the invention is a bacterial cell containing the hybrid cloning vehicle of the invention.

25

Preferred bacterial cells containing the hybrid cloning vehicles are E. coli cells, Bacillus subtilis cells, Pseudomonas, Aerobacter, Salmonella, Proteus and Serratia cells.

30

The said bacterial cells containing the hybrid cloning vehicle of the invention may further contain a second cloning vehicle, said second cloning vehicle containing a sequence of nucleotide bases coding for a eukaryotic  
35 protein.

Again, E. coli cells, Bacillus subtilis cells, Pseudomonas,

1 Aerobacter, Salmonella, Proteus and Serratia cells are preferred.

A further subject matter of the invention is a method  
5 for suppressing the degradation of abnormal proteins in a bacterial cell, comprising producing the DNA fragment of the invention, inserting said DNA fragment into a cloning vehicle to produce a hybrid cloning vehicle, and transforming a bacterial cell by introducing said hybrid cloning  
10 vehicle therein.

In the said method of the invention the cloning vehicle is preferably a plasmid and the bacterial cells are E. coli cells, Bacillus subtilis cells, Pseudomonas, Aerobacter,  
15 Salmonella, Proteus or Serratia cells.

The T-even DNA from which the DNA fragment used in the method of the invention stems is preferably cytosine-containing and nonglucosylated. The DNA fragment used is preferably isolated from T4 bacteriophage.  
20

Another subject matter of the invention is a method for producing a DNA fragment consisting essentially of a sequence of nucleotide bases coding for protein that  
25 suppresses degradation of abnormal proteins in bacterial cells, comprising treating the DNA of a T-even bacteriophage with a restriction enzyme to cleave the DNA into fragments, at least one of the said fragments coding for protein that suppresses degradation in bacterial cells,  
30 inserting said DNA fragments into cloning vehicles to produce hybrid cloning vehicles, transforming bacterial cells by introducing said hybrid cloning vehicles therein, and selecting the transformants exhibiting suppressed degradation of abnormal proteins.

35

In this method of the invention the cloning vehicle is again preferably a plasmid and the bacterial cells are



- 1 E. coli cells, Bacillus subtilis cells, Pseudomonas, Aero-  
bacter, Salmonella, Proteus or Serratia cells.

The T-even DNA from which the DNA fragment used in this  
5 method of the invention stems is preferably cytosine-  
containing and nonglucosylated. The DNA fragment used  
is preferably isolated from T4 bacteriophage.

The said method of the invention preferably further com-  
10 prises removing said hybrid cloning vehicle from a selected  
transformant and excising said DNA fragment from said  
hybrid cloning vehicle.

A further subject matter of the invention is a nucleic  
15 acid consisting essentially of a sequence of nucleotide  
bases coding for protein that suppresses degradation of  
abnormal proteins in bacterial cells.

The said nucleic acid is a DNA fragment which preferably  
20 codes for protein that suppresses degradation in E. coli  
cells, or in Bacillus subtilis or in the other microorganisms  
mentioned above.

A further subject matter of the invention is a hybrid  
cloning vehicle comprising a cloning vehicle and the said  
25 DNA fragment.

Said cloning vehicle is preferably a plasmid, the plasmid  
pBR 325 being especially preferred.

30 Preferably said cloning vehicle further comprises a  
sequence of nucleotide bases coding for a eukaryotic pro-  
tein.

A further subject matter of the invention is a bacterial  
35 cell containing the said hybrid cloning vehicle.

The said bacterial cell is preferably an E. coli cell or a Bacillus  
subtilis cell or one of the other microorganisms mentioned above.

- 1 Another subject matter of the invention finally is a method  
for suppressing the degradation of abnormal proteins in  
a bacterial cell comprising producing the above-mentioned  
DNA fragment, inserting said DNA fragment into a cloning  
5 vehicle to produce a hybrid cloning vehicle, and trans-  
forming a bacterial cell by introducing said hybrid  
cloning vehicle therein.

- In this method of the invention the cloning vehicle used  
10 is preferably a plasmid and the bacterial cell is an E.  
coli cell or a Bacillus subtilis cell or one of the other  
microorganisms mentioned above.

- The method of isolating the stabilizing DNA fragment  
according to the present invention comprises treating  
15 the DNA of a T-even bacteriophage with a restriction  
enzyme to cleave the DNA into fragments, at least one of  
said fragments coding for protein that causes the  
suppression of degradation of abnormal proteins in bacterial  
cells, inserting said DNA fragments into cloning vehicles,  
20 such as bacterial plasmids, to produce hybrid cloning ve-  
hicles, transforming bacterial cells by introducing said  
hybrid cloning vehicles therein, and selecting the trans-  
formants which exhibit suppressed degradation of abnormal  
proteins. As used herein, the term "hybrid cloning vehicle"  
25 refers broadly to a cloning vehicle, such as a bacterial  
plasmid, containing a T-even DNA insert.

- The method of the invention leads to an increase in the  
yield of proteins expressed by cloned DNA in a bacterial  
30 cell by inserting the DNA fragment into a cloning vehicle,  
such as a bacterial plasmid, to produce a hybrid cloning  
vehicle, and transforming the bacterial cell containing  
the cloned DNA by introducing said hybrid cloning vehicle  
into said bacterial cell.

35

1 Detailed description of the invention

The invention will now be explained in more detail with reference being made to T4 phage which is preferred for  
5 the isolation of the DNA fragment of the invention. It is expressly stated however, that the invention is not restricted to this embodiment, but that other T-even phages can also be used.

10 The genetic map of T4 phage is known to be circular and to contain about 150 genes. About 40 different T4 gene products, each coded by a specific T4 gene, interact to produce the coat proteins which form the mature virus particle. It is not known how many genes are responsible  
15 for suppressing degradation of abnormal proteins in bacterial hosts. Nor is it known which proteins are expressed by these genes. However, as a result of the practices of the present invention, it has been learned that a DNA fragment which codes for protein that functions  
20 to suppress degradation of abnormal proteins in bacterial cells originates from the vicinity of gene 49 of the T4 genetic map.

Wais, et. al., in Virology, 39, 153 (1969), have reported  
25 that T4 phage is able to replicate when injected into a variety of bacteria, including E. coli strain B/4, Salmonella, Aerobacter, Proteus, and Serratia. Thus, the genetic machinery of T4 is unimpaired and is able to function essentially normally when inserted in a wide  
30 variety of host cells.

The genetic nucleic acid present in the core of the T4 phage particle is double-stranded DNA. T4 DNA comprises about  $3.6 \times 10^5$  base pairs (MW ca.  $1.2 \times 10^8$ ). There are twice as many A-T base pairs as G-C base pairs. T4 DNA is unusual in that it contains the base 5-OH-methylcytosine in place of the more usual cytosine. Moreover, one or more glucose residues are attached to some of the 5-CH<sub>2</sub>OH cytosine groups in the T4 DNA. 5-OH-methylcytosine, like cytosine, forms base pairs with guanine. The presence of 5-OH-methylcytosine and its glucose derivatives in place of cytosine has no bearing on the genetic properties of T4 phage. The biological significance of the unusual base has not yet been clearly established although it is believed that its function is to protect T4 DNA from a phage specific enzyme which destroys unmodified DNA.

In accordance with the present invention, a process is disclosed for isolating a specific DNA fragment from T-even phage particles which will suppress degradation of abnormal proteins, such as foreign proteins encoded by cloned DNA, in bacterial cells. The process begins with the extraction of DNA from the capsids of T-even phage particles.

T-even DNA may be extracted from the capsids of the T-even particles by well known methods. Both chemical or mechanical methods are known to remove the DNA from the T-even particles although chemical methods are preferred since they are less likely to damage the DNA. For purposes of the present invention, it is preferable that the DNA come from T-even mutants in which the DNA is cytosine-containing and nonglucosylated. This form of DNA is pre-

ferred since most restriction enzymes will not act on wild-type T4 DNA. Furthermore, wild-type T4 DNA may not be transcribed in host cells as well as cytosine-containing, nonglucosylated DNA.

After the DNA has been extracted from the T-even phage particles, the DNA is digested with a suitable restriction endonuclease. The restriction enzyme scans the DNA strand and cleaves it into fragments whenever a particular short sequence of nucleotides is encountered. Each restriction enzyme therefore cleaves the T-even DNA into a characteristic set of fragments which can be separated, if desired, by well known methods such as gel electrophoresis. It is essential that the restriction enzyme not cleave the DNA within the gene(s) responsible for suppressing degradation of abnormal proteins. A variety of restriction enzymes have been found suitable for the practice of the present invention, including such well known endonucleases as Pst I and Eco RI.

To isolate the specific T-even DNA fragment containing the stabilizing gene(s), the fragments are inserted into suitable cloning vehicles to produce hybrid cloning vehicles. Both viruses and plasmids are suitable cloning vehicles; however, bacterial plasmids carrying genes which serve as recognition markers, such as antibiotic resistance, may be preferred. For example, the readily available plasmid pBR 325, which confers resistance to ampicillin, chloramphenicol, and tetracycline, or the readily available plasmid pBR 322, which confers resistance to ampicillin and tetracycline, are suitable cloning vehicles for the present invention.

~~BAD ORIGINAL~~

The T-even DNA fragments can be inserted into the cloning vehicles, such as the bacterial plasmids, by a variety of enzymatic techniques. When the T-even DNA has been cleaved with a restriction enzyme leaving "sticky ends", the same restriction enzyme can be used to cleave open the appropriate bacterial plasmid. The bacterial plasmid will then have matching sticky ends and the DNA fragments can be directly annealed to the bacterial plasmids. However, if the restriction enzyme leaves blunt ends, the enzyme terminal transferase can be used to provide a short sequence of identical bases, such as four cytosines, to the DNA fragments. The fragments can then be annealed to the plasmid DNA to which a complementary sequence of bases (four guanines) have been added.

The hybrid cloning vehicles are next inserted into bacterial host cells. Treatment with a dilute solution of calcium chloride is known to render the cell walls permeable to plasmids. E. coli cells have been found to be suitable host cells for expressing the stabilizing DNA fragment although the method of the present invention is not confined to these cells. E. coli is classified as a gram-negative species of bacteria. Other gram-negative bacteria such as Pseudomonas, Aerobacter, etc., are also suitable hosts for expressing the stabilizing function of the DNA fragment. With suitable modification in the Shine-Dalgarno sequence, gram-positive bacteria, such as Bacillus subtilis, will also serve as suitable hosts for the stabilizing DNA fragment. The modification techniques are conventionally known in the art.

To select the host cells which have been transformed by the hybrid cloning vehicles, bacteria are grown first in a non-

SAD 0072925

selective medium and then in a selective medium. For example, the restriction enzyme Pst I cuts the plasmid of pBR 325 in the midst of the gene which confers ampicillin resistance, but leaves the genes which confer chloramphenicol and tetracycline resistance intact. Thus, one can select the transformed cells containing inserts in the Pst I site of pBR 325 by screening for resistance to chloramphenicol and tetracycline and sensitivity to ampicillin.

To isolate those transformants containing the stabilizing DNA fragment, the transformants are screened for those which exhibit suppressed degradation of abnormal proteins. A test based upon the ability of temperature sensitive phage mutants to propagate in the transformants has been found suitable for this purpose. At appropriate temperatures, the phage mutant will only grow in host cells having defective mechanisms for degradation of abnormal proteins. For example, the phage mutant known as  $\lambda_{0ts}$  is a  $\lambda$  phage with a defect in gene 0. The  $\lambda_0$  protein is vital to the survival of the virus. Wild-type phage is able to propagate in E. coli at 30° and at 39°C.  $\lambda_{0ts}$ , however, is unable to propagate at 39°C unless the degradation mechanism of the E. coli cells is impaired (see Simon et al., Proc. Nat. Acad. Sci. USA, 76, 1623 (1979)). Thus, the transformants containing the desired T-even DNA fragment can be selected by their ability to propagate the  $\lambda_{0ts}$  phage mutants at 30°C and at 39°C. If desired, these transformants can be tested further for their ability to degrade abnormal proteins and protein fragments by methods described in Simon et al., Nature, supra.

In this manner transformants are isolated having an impaired degradation mechanism. The transformants contain

a hybrid cloning vehicle such as a plasmid, in which a DNA fragment from T-even phage has been inserted. This DNA fragment is functional in bacteria, and contains the genetic information required to inhibit abnormal protein degradation.

The plasmid can be removed from the selected transformants and introduced into other host cells where it will inhibit degradation in the new host cells. The new host cells are not confined to E. coli but may be any of a wide variety of bacterial cells, including Pseudomonas, Aerobacter, etc., and, with suitable modification of the Shine-Dalgar sequence, Bacillus subtilis, etc. The new host cells may additionally carry an appropriate recombinant plasmid for producing eukaryotic proteins. The presence of the stabilizing DNA fragment will increase dramatically the yields of the eukaryotic proteins.

Alternatively, the T-even DNA fragment may be excised from the hybrid plasmid by treatment with a restriction enzyme, for example, Pst. I. The DNA fragment may then be inserted into a cloning vehicle, such as a plasmid, already carrying a gene for producing a eukaryotic protein. When the new recombinant plasmid is introduced into a host cell, the yields of the eukaryotic protein will be greatly increased.

After the stabilizing DNA fragment has been isolated, it may be subjected to further analysis and study. For example, the DNA fragment can be sequenced by laborious but well known techniques. The DNA fragment may also be subcloned to find the smallest DNA fragment which would inhibit degradation in bacterial cells. Subcloning



can be accomplished by digesting the stabilizing DNA fragment with a variety of restriction enzymes in order to cut it into smaller fragments. Each of these pieces can then be inserted into a plasmid and then cloned in a bacterial host. The hosts can then be screened for impaired degradation. In this manner, the smallest DNA fragment can be isolated which codes for protein that suppresses degradation of abnormal proteins in bacteria.

The practices of the present invention may be further illustrated by the following examples.

Example 1

For purposes of testing the practices of the present invention, DNA was extracted by well known methods from T4 mutants having the following mutations: alc<sup>-</sup>, den A<sup>-</sup>, den B<sup>-</sup>, 42<sup>-</sup>, 56<sup>-</sup>. These mutations result in T4 particles having cytosine-containing, nonglycosylated DNA.

The DNA from the T4 mutants was cleaved with the restriction endonuclease Pst I. This restriction enzyme recognizes the nucleotide sequence CTGCA<sup>+</sup>G and cuts the T4 DNA between A and G wherever this sequence appears. Digestion of T4 DNA with Pst I produced about 35 DNA fragments of various lengths.

At the same time, the bacterial plasmid known as pBR 325 was also cleaved with Pst I. Pst I cleaved pBR 325 provides chloramphenicol and tetracycline resistance but not ampicillin resistance. The T4 DNA fragments were then directly annealed to the Pst I cleaved pBR 325 plasmids to produce hybrid plasmids.

E. coli cells, strain C600 (a K12 strain) were then transformed by mixing with the pBR 325 plasmids in a dilute solution of calcium chloride. The transformed bacteria were grown first in a nonselective medium, and then in a selective medium which screened for chloramphenicol and tetracycline resistance and ampicillin sensitivity. In this way individual transformants which had taken up the hybrid pBR 325 plasmids were isolated and cultured as colonies. Each of the colonies was given a number.

To isolate the E. coli transformants which contain the stabilizing DNA fragment, individual transformants were cultured. The cultures were then infected with  $\lambda$ 0ts mutants and incubated as plate assays at 30°, 37° and 39°C. The number of plaques per plate for each culture was counted. The relative efficiency of plaque formation for selected cultures is shown in Table 1.

TABLE 1

<u>PLASMID</u>	<u>Efficiency of Plaque Format At:</u>		
	<u>30°C</u>	<u>37°C</u>	<u>39°C</u>
pBR 325	1	0.38	0.02
Pst 30	1	0.78	0.78
Pst 83	1	1.43	0.76
Pst 91	1	1.43	1.11

In Table 1, the designation pBR 325 indicates host cells containing the plasmid pBR 325. These cells served as a control. The designation Pst 30 indicates host cells containing the plasmid pBR 325 with the T4 DNA insert of colony 30. Similarly Pst 83 and Pst 91 indicate host cells containing the plasmid pBR 325 with the T4 DNA inserts of colonies 83 and 91 respectively.

As can be seen in Table 1, the ability of  $\lambda$ 0ts to propagate at 39°C was drastically reduced in E. coli cells having only the pBR 325 control. However,  $\lambda$ 0ts was able to propagate well at 39°C in E. coli cells having the T4 DNA inserts of colonies 30, 83 and 91. The ability of  $\lambda$ 0ts to propagate at 39°C was due to the suppressed degradation of abnormal protein in the E. coli cells having the T4 DNA inserts of colonies 30, 83 and 91.

#### Example 2

The hybrid plasmids of Example 1 were introduced into E. coli cells, strain SG 13062 (a K12 strain). Transformants were examined for their ability to degrade puromycyl protein fragments by the methods described in Simon et al., Nature, supra. The results are shown in Fig. 1, wherein the designations are the same as in Example 1.

As can be seen in Fig. 1, E. coli cells containing T4 DNA fragments from colonies 83 and 91 show substantially lower levels of degradation than E. coli cells containing only the pBR 325 plasmid. Moreover, these E. coli cells exhibited no change in the turnover rate of normal proteins.

#### Example 3

The hybrid plasmid Pst 91 was introduced into E. coli cells, strains SG 13062 and SG 13069 (both K12 strains). SG 13062 served in this example as a wild-type E. coli strain. SG 13069 is identical to SG 13062 except that SG 13069 carries the mutation designated lon<sup>-</sup>. This mutation of the E. coli genome reduced the efficiency of the degradation mechanism. The E. coli transformants were examined for their ability to degrade puromycyl polypeptides. The



results are shown in Fig. 2. The results demonstrate that E. coli cells having the stabilizing T4 DNA fragment exhibit less degradation of abnormal proteins than E. coli lon<sup>-</sup> mutants. Fig. 2 also shows that degradation is smallest in lon<sup>-</sup> mutants having the stabilizing T4 DNA fragment.

#### Example 4

E. coli cells of the strain designated 294 (a K12 strain) were transformed with plasmid Pst 91 or with pBR 325. The E. coli cells had previously been transformed with the plasmid designated PACY184IF. This plasmid contains the gene which codes for human fibroblast interferon. The transformants were cultured and the interferon production was assayed. The results are shown in Table 2.

Table 2

<u>PLASMIDS</u>	<u>INTERFERON (units/ml culture)</u>
PACY184IF	150
PACY184IF + pBR 325	150
PACY184IF + Pst 91	600

Table 2 demonstrates that E. coli clones carrying the gene for human interferon and the stabilizing T4 DNA fragment yielded four times as much interferon as clones not having the T4 DNA fragment.

#### Example 5

The T4 DNA fragment was excised from Pst 91 with Pst I and inserted into the plasmid designated 177. Plasmid 177 contained the gene coding for human fibroblast interferon. E. coli cells, strain 294, were transformed with the new plasmid designated 177-91. The transformants were cul-

tured and the interferon was extracted after freeze-thaw cycles and assayed. The results are shown in Table 3.

Table 3

<u>PLASMID</u>	<u>INTERFERON (units/ml culture)</u>
177	150
177-91	600

As in Example 4, the E. coli clones carrying the gene for human interferon and the stabilizing T4 DNA fragment yielded four times as much interferon as clones not carrying the T4 DNA fragment.

Example 6

E. coli cells, strain 294 were transformed with the plasmid 177-91 as in Example 5. The transformants were cultured and the interferon was extracted following treatment of the cells with the detergent Triton X100. The interferon was assayed and the results are shown in Table 4.

Table 4

<u>PLASMID</u>	<u>INTERFERON (units/ml culture)</u>
177	300
177-91	2400

In this case, the host cells having the stabilizing T4 DNA fragment yielded eight times as much interferon as cells without the fragment.

While the invention has been described with reference to specific embodiments, this should not be construed to limit the spirit or the scope of the invention.

BAD ORIGINAL

## 1 WHAT IS CLAIMED IS:

1. A DNA fragment isolated from the DNA of a T-even bacteriophage, said DNA fragment consisting essentially  
5 of a sequence of nucleotide bases which code for protein that suppresses degradation of abnormal polypeptides in bacterial cells.
2. The DNA fragment of Claim 1 wherein said fragment  
10 is isolated from T4 bacteriophage.
3. The DNA fragment of Claim 1 wherein said T-even DNA is cytosine-containing and nonglucosylated.
- 15 4. A hybrid cloning vehicle comprising a cloning vehicle and the DNA fragment of Claim 1.
5. The hybrid cloning vehicle of Claim 4 wherein said cloning vehicle is a plasmid.  
20
6. The hybrid cloning vehicle of Claim 4 wherein said cloning vehicle further comprises a sequence of nucleotide bases coding for a eukaryotic preferably human protein.  
25
7. The hybrid cloning vehicle of Claim 6 wherein said human protein is human interferon.
8. A bacterial cell containing the hybrid cloning vehicle  
30 of Claim 6.
9. A bacterial cell containing the hybrid cloning vehicle of Claim 4 and further containing a second cloning vehicle, said second cloning vehicle containing a  
35 sequence of nucleotide bases coding for a eukaryotic protein.

- 1 10. A method for suppressing the degradation of abnormal  
proteins in a bacterial cell, comprising producing  
the DNA fragment of Claim 1, inserting said DNA frag-  
ment into a cloning vehicle to produce a hybrid cloning  
5 vehicle, and transforming a bacterial cell by intro-  
ducing said hybrid cloning vehicle therein.
11. A method for producing a DNA fragment consisting  
essentially of a sequence of nucleotide bases coding  
10 for protein that suppresses degradation of abnormal  
proteins in bacterial cells, comprising treating the  
DNA of a T-even bacteriophage with a restriction enzyme  
to cleave the DNA into fragments, at least one of  
said fragments coding for protein that suppresses  
15 degradation in bacterial cells, inserting said DNA  
fragments into cloning vehicles to produce hybrid cloning  
vehicles, transforming bacterial cells by introducing  
said hybrid cloning vehicles therein, and selecting the  
transformants exhibiting suppressed degradation of  
20 abnormal proteins.
12. The method of Claim 11 further comprising removing  
said hybrid cloning vehicle from a selected trans-  
formant and excising said DNA fragment from said hybrid  
25 cloning vehicle.
13. A nucleic acid consisting essentially of a sequence  
of nucleotide bases coding for protein that suppresses  
degradation of abnormal proteins in bacterial cells.  
30
14. A DNA fragment in accordance with Claim 13.
15. A hybrid cloning vehicle comprising a cloning vehicle  
and the DNA fragment of Claim 14.  
35
16. A bacterial cell containing the hybrid cloning vehicle  
of Claim 15.

- 1 17. A method for suppressing the degradation of abnormal  
proteins in a bacterial cell comprising producing  
the DNA fragment of Claim 14, inserting said DNA  
fragment into a cloning vehicle to produce a hybrid  
5 cloning vehicle, and transforming a bacterial cell  
by introducing said hybrid cloning vehicle therein.

10

15

20

25

30

35



1

5

10

15


20

25

30

35

Fig. 1.



1

5

10

15

20

25

30

35




Fig. 2.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**